<p>National governments are routinely pressured by pharmaceutical industries, by means of their lobbying expenditures and political contributions, to protect their IP rights and set their own value-based, as opposed to value in health care, prices for the drugs they manufacture. At the same time, international organizations such as the World Trade Organization continue to strive to negotiate agreements (eg. Trade Related Aspects of Intellectual Property Rights, or TRIPS) to bring a meaningful balance between developed and developing nations because the latter face severe challenges of access to essential drugs and the courts are engaged in judicial activism to prevent evergreening and serve the common good while ruling on cases that appear before them. Hence. Pharma-Patents in India and the USA-a Juristic Study compares pharma-patents in India and the United States while examining the role of the World Trade Organization in bringing a balance between developed and developing nations via TRIPS and its impact on the Indian Patent Act 1970.</p>
